UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2005
GENEREX BIOTECHNOLOGY CORPORATION
------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 000-25169 98-0178636
-------- --------- ----------
(State of Other (Commission (IRS Employer
Jurisdiction of File Number) Identification
Incorporation) Number)
33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J 2G2
----------------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (416) 364-2551
N/A
--------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 3, 2005, Generex Biotechnology Corporation (the "Company")
issued a press release announcing that Oral-lyn(TM), the Company's proprietary
oral insulin spray formulation has been approved for commercial marketing and
sale by the Ecuadorian Ministry of Public Health for the treatment of both
Type-1 and Type-2 diabetes. A copy of the press release is attached as an
exhibit to this report.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release of Generex Biotechnology Corporation issued
May 3, 2005
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: May 3, 2005 By: /s/ Rose C. Perri
----------------------------
Chief Operating Officer and
Chief Financial Officer
(principal financial officer)
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION
- -------------- -----------
99.1 Press release of Generex Biotechnology Corporation issued
May 3, 2005